The overall goal of the present NCI-sponsored Training Program in Medical Oncology at The University of Chicago is to provide outstanding scientific training for postdoctoral fellows in order to prepare them for careers as independent investigators in academic oncology. The direction of the program -- the vertical integration of training in basic and clinical oncology research -- has not changed since the program's inception; however, we have significantly enhanced our training in patient-oriented research in response to a national need. The proposed training in Oncology encompasses several academic units within the Division of Biologic Sciences and includes the Section of hematology/oncology, the Maclean Center for Clinical Medical Ethics in the Department of Medicine, the Department of Health Studies as well as involves a number of research laboratories of clinical and basic research scientists who are members of the University of Chicago Comprehensive Cancer Center. ? ? The proposed research training faculty preceptors interact on a number of collaborative research and training efforts. This interaction has been fostered by the close proximity of the investigators at the University of Chicago campus and particularly by their research activities within our comprehensive cancer center. Generally, research programs fall into three distinct areas -- patient-oriented research, translational, and basic science research. Our extensive inpatient and outpatient facilities promote a comprehensive clinical training experience, while our research laboratories allow for the acquisition of basic science skills. Our training program seeks to produce physician-scientists or clinical researchers who possess the skills necessary to bridge the gaps that exist between clinical medicine and basic science. Physicians completing our training program are trained to become the future academic leaders in hematology/oncology who are able to vertically integrate their knowledge from the bedside to the bench or from the bench to the bedside. Trainees will be provided with a problem-oriented approach to research (either a process or an approach within a disease or a specific basic science issue) and will be trained to study research problems using both laboratory and clinical research techniques.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009566-19
Application #
6933026
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
1987-09-05
Project End
2007-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
19
Fiscal Year
2005
Total Cost
$354,954
Indirect Cost
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
West, Allison H; Blazer, Kathleen R; Stoll, Jessica et al. (2018) Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. Fam Cancer 17:495-505
Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000
Veneris, Jennifer Taylor; Darcy, Kathleen M; Mhawech-Fauceglia, Paulette et al. (2017) High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol 146:153-160
Sweis, Randy F; Medved, Milica; Towey, Shannon et al. (2017) Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer 15:207-212
Saha, Poornima; Amico, Andrea L; Olopade, Olufunmilayo I (2016) Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain. Clin Breast Cancer 16:e61-3
University of Chicago Hematopoietic Malignancies Cancer Risk Team (2016) How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood 128:1800-1813
Sweis, Randy F; Spranger, Stefani; Bao, Riyue et al. (2016) Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res 4:563-8
Curran, Emily; Chen, Xiufen; Corrales, Leticia et al. (2016) STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia. Cell Rep 15:2357-66
Sweis, Randy F; Ratain, Mark J (2016) Reply to T.A. Yap et al. J Clin Oncol 34:2432-3
Pettit, Kristen; Stock, Wendy; Walter, Roland B (2016) Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia. Leuk Lymphoma 57:1527-33

Showing the most recent 10 out of 59 publications